These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 20041328)

  • 21. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
    Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
    Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Kakeji Y; Oki E; Egashira A; Sadanaga N; Takahashi I; Morita M; Emi Y; Maehara Y
    Oncology; 2009; 77(1):49-52. PubMed ID: 19556809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
    Iwase H; Shimada M; Tsuzuki T; Ina K; Sugihara M; Haruta J; Shinoda M; Kumada T; Goto H
    Oncology; 2011; 80(1-2):76-83. PubMed ID: 21659786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.
    Kim H; Park JH; Bang SJ; Kim DH; Cho HR; Kim GY; Min YJ
    Jpn J Clin Oncol; 2005 Dec; 35(12):727-32. PubMed ID: 16332720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
    Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
    Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
    Baba E; Fujishima H; Kusaba H; Esaki T; Ariyama H; Kato K; Tanaka R; Mitsugi K; Shibata Y; Harada M; Nakano S
    Anticancer Res; 2009 May; 29(5):1727-32. PubMed ID: 19443394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
    Polyzos A; Tsavaris N; Kosmas C; Polyzos K; Giannopoulos A; Felekouras E; Nikiteas N; Kouraklis G; Griniatsos J; Safioleas M; Stamatakos M; Pikoulis E; Papachristodoulou A; Gogas H
    Anticancer Res; 2006; 26(5B):3749-53. PubMed ID: 17094396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):605-12. PubMed ID: 23338050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
    Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
    Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y
    Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
    Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
    Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
    Zang DY; Yang DH; Lee HW; Hwang SW; Song HH; Jung JY; Kwon JH; Kim HJ; Kim JH; Park SR; Kim MJ; Jang KM; Park CK; Kim JH; Lee BH
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):509-16. PubMed ID: 18481067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.